Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ABM-168 |
Synonyms | |
Therapy Description |
ABM-168 inhibits MEK1 and MEK2, potentially resulting in antitumor activity (Cancer Res 2023;83(7_Suppl):Abstract nr 475). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ABM-168 | ABM168|ABM 168 | MEK1 Inhibitor 26 MEK2 Inhibitor 24 | ABM-168 inhibits MEK1 and MEK2, potentially resulting in antitumor activity (Cancer Res 2023;83(7_Suppl):Abstract nr 475). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05831995 | Phase I | ABM-168 | Safety and Effectiveness of ABM-168 in Adults With Advanced Solid Tumors. | Recruiting | USA | 0 |